Viral Antigen Ingredients TRIZ Cases
- Intratumoral Influenza Vaccines for Cold Tumor Immunotherapy
Intratumoral influenza vaccination turns cold tumors hot, boosting immune cell infiltration and checkpoint blockade response.
- Multi-MHC Polypeptide Vaccines for Broad HLA-DR Coverage
Promiscuous 18-55 amino acid polypeptides broaden HLA-DR presentation while preserving antigen-specific T-cell activation in cancer vaccines.
- HIV-1 V3 Glycopeptide Immunogens for Broadly Neutralizing Antibodies
Man9-V3 glycopeptide immunogens mimic native Env V3-glycan epitopes to induce broadly neutralizing HIV-1 antibodies.
- Anti-STEAP1 T-Cell Redirecting Antibody for Targeted Tumor Killing
A heterodimeric anti-STEAP1 antibody redirects T-cell cytotoxicity to prostate tumor cells while limiting off-target effects.
- Recombinant Adenovirus Construction for ASFV EP153R-EP402R Expression
TOPO cloning, LR recombination, and AD293 packaging enable a recombinant adenovirus expressing ASFV EP153R-EP402R for vaccine development.
- RNA-LPX Therapeutic Vaccine for HPV-Positive Tumor Regression
RNA-LPX encoding HPV E6/E7 drives durable T cell responses to shrink HPV-positive tumors, improve survival, and reduce treatment morbidity.
- Attenuated Avian Reovirus Vaccine Strains for Variant Protection
New attenuated avian reovirus strains match circulating isolates to safely protect poultry from viral arthritis, tendon swelling, and mortality.
- Tumor Antigen-Specific T Cell Expansion via Sequential DC Co-Culture
Sequential dendritic cell co-culture and IFNγ-based enrichment raise tumor-specific T cell yield and concentration for cancer immunotherapy.
- Porcine Alveolar Macrophage Cell Line for Multi-Passage ASF Virus Growth
Fetal porcine lung alveolar macrophage cells enable multi-passage ASF virus replication, supporting vaccine development and diagnostic research.
- CLuTV Detection and Vaccine Strategy for Lumpsucker Mortality
Novel CLuTV detection and vaccine tools help explain unexplained lumpsucker deaths and reduce mortality in aquaculture.
- HBV-Specific T Cell Response via MHC-E CMV Vector Engineering
A CMV vector lacking UL128, UL130, UL146, and UL147 drives MHC-E-restricted CD8+ T cells to overcome HBV immunotolerance.
- CA-CAS-01-A Cell Line for Stable ASFV Vaccine Propagation
A derived MA104 cell line enables stable ASFV propagation while preserving protective efficacy through naturally attenuated virus production.
- Pepmix CTL Generation for Broad Multiviral Specificity
Peptide mixtures stimulate PBMCs to rapidly expand broad-spectrum CTLs for multiple viral antigens without infectious virus or dendritic cells.
- mAb-52 Antibody Composition for SARS-CoV-2 Variant Neutralization
Targeting a conserved SARS-CoV-2 spike RBD, mAb-52 blocks ACE2 binding to neutralize escape variants and reduce viral load.
- Modified CHO Cell Line for Stable MVA Vaccine Production
Engineered CHO cells expressing CP77, K1L, and SPI-1 enable stable high-titer MVA replication without primary CEF contamination limits.
- HBV Vaccine Adjuvant Composition for Th1 and Th2 Immune Response
Combining aluminum adjuvant with motif-defined CpG oligodeoxynucleotides boosts HBV antibody response while adding Th1 immunity.
- Nanoparticle Poxvirus Vaccines for Scalable Neutralizing Immunity
Nanoparticle display of L1, A33, and B5 antigens improves scalable poxvirus vaccine manufacturing while strengthening neutralizing protection.
- Shingles Vaccine Composition Using CpG Adjuvant to Lower Reactogenicity
A VZV gE vaccine paired with a TLR9 CpG adjuvant maintains immune response while reducing reactogenicity and severe adverse events.
- Ferritin HIV Trimer Nanoparticles for Germinal Center Targeting
Glycosylated HIV trimers on self-assembling ferritin nanoparticles use MBL and complement transport to reach germinal centers and boost antibody responses.
- Modified Immunogenic Proteins for Germline-Targeted HIV bnAb Priming
Engineered HIV immunogens expose conserved epitopes and stabilize trimers to prime precursor B cells and guide broadly neutralizing antibody maturation.
- hMPV Fusion Protein Antibodies for Broad Viral Neutralization
Monoclonal antibodies targeting conserved hMPV F protein epitopes neutralize genotypes A and B and help inhibit lung infection.
- Inactivated Avian Reovirus Vaccination With Polymer-Lipid Adjuvant
An inactivated reovirus vaccine with a polymer-lipid adjuvant enables safe early chick vaccination and protective immunity within days 1-14.
- Multi-Site DNA Vaccine Injection for Faster Salmon Immunity
Multiple sub-effective intramuscular DNA vaccine doses given at different sites speed salmon immunity while reducing viral load and tissue damage.
- HIV-1 Envelope V2 Loop Optimization for Broad bnAb Induction
Optimized V2 loop and CD4-binding HIV envelopes improve cross-reactive neutralizing antibody induction for broader HIV-1 vaccine response.
- IL-4R Antagonist Therapy for Steroid-Refractory Severe Asthma
Targeting IL-4R signaling offers severe asthma and ABPA control while avoiding the systemic toxicities linked to high-dose corticosteroids.
- HPV16 Immunogenic Epitopes for HLA-Restricted T-Cell Targeting
Novel HPV16 E2, E6, and E7 epitopes matched to common HLA alleles improve T-cell targeting and help overcome CTL dysfunction in HNSCC.
- Cationic Lipid Adjuvants for Type I Interferon and T Cell Activation
Cationic lipids such as R-DOTAP boost type I interferon signaling and antigen cross-presentation to drive stronger cytotoxic T cell responses.
- Mock Virus Particle Quantification for In-House Viral Clearance
Non-infectious mock virus particles enable in-house viral clearance quantification, avoiding third-party infectivity assays and delays.
- RNA Booster Sequence for High Transient Vaccine Expression
A 9-nucleotide RNA Booster sequence improves RNA stability and transgene expression, enabling transient vaccination with lower vector doses.
- Canine Melanoma Vaccine Composition With Immune Checkpoint Inhibition
An adenovirus vaccine pairs a canine melanoma polyepitope with HSV-1 gD to overcome weak treatment options and trigger effector and memory T cells.